Welcome to our dedicated page for Applied Genetic news (Ticker: AGTC), a resource for investors and traders seeking the latest updates and insights on Applied Genetic stock.
The AGTC (Applied Genetic Technologies Corporation) news archive on Stock Titan covers the company’s history as a clinical-stage biotechnology developer of adeno-associated virus (AAV)-based gene therapies for rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. News releases repeatedly describe AGTC’s focus on inherited retinal diseases, with its most advanced clinical programs in X-linked retinitis pigmentosa (XLRP) and achromatopsia due to CNGB3 variants (ACHM CNGB3).
Readers will find detailed coverage of the strategic transaction in which a portfolio company of Syncona Limited agreed to acquire AGTC through a tender offer and subsequent merger. Multiple releases from October through December 2022 outline the tender offer terms, the board’s unanimous recommendation, reminders to shareholders about tender deadlines, and the final confirmation that the acquisition closed and AGTC became an indirect, wholly owned subsidiary of Syncona Limited, with its common stock delisted from the Nasdaq Global Stock Market.
The archive also includes earlier corporate updates, such as announcements about AGTC’s participation in investor conferences and reiterations of its development strategy in AAV-based gene therapy, inherited retinal disease programs, and preclinical work in optogenetics, otology and CNS disorders. In addition, later news from Beacon Therapeutics references laru-zova (laruparetigene zovaparvovec), described in a presentation title as “AGTC-501,” providing continuity for those tracking the historical XLRP program originally developed at AGTC.
Investors, researchers and industry observers can use this news page to review AGTC’s public communications, understand the rationale and structure of the Syncona acquisition, and follow how AGTC’s legacy XLRP asset is referenced in subsequent clinical trial updates from Beacon Therapeutics.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced that CEO Sue Washer will participate in the OIS Gene Therapy Innovation Showcase on February 18, 2021, from 12 PM to 3 PM CST. The virtual event will feature a market overview, a start-up spotlight, and a panel discussion focused on gene therapy in eye care. Registration is complimentary. AGTC specializes in AAV-based gene therapies targeting rare ophthalmic and CNS diseases, with ongoing clinical trials in conditions like X-linked retinitis pigmentosa and achromatopsia.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced that executives will present at the 4th Annual Gene Therapy for Rare Disorders event from February 22-25, 2021. Vice President Dave Knop will lead a workshop focused on enhancing gene therapy manufacturing processes, while Executive Director Jill Dolgin will participate in a panel discussing patient advocacy. The sessions aim to address the importance of scalable manufacturing and patient input in gene therapy development, enhancing the understanding and treatment of rare diseases.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced its financial results for the quarter ended December 31, 2020, reporting a net loss of $15.5 million. While there was no revenue, the company expects cash runway into 2023 due to a recent public offering generating $69.2 million in proceeds. AGTC plans multiple data readouts for its XLRP and ACHM clinical programs, signaling progress in clinical trials. Significant improvements in visual sensitivity were observed in Phase 1/2 trials for XLRP and ACHM, with key data anticipated throughout 2021 and 2022.
Summary not available.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) will announce financial results for the fiscal quarter ending December 31, 2020, on February 11, 2021, before market opens. A conference call is scheduled for the same day at 8:00 AM ET to discuss the results and provide updates. AGTC focuses on gene therapies for rare diseases, with clinical trials for X-linked retinitis pigmentosa and achromatopsia. The company aims to address significant unmet clinical needs using its advanced AAV technology.
Applied Genetic Technologies Corporation (AGTC) announced a public offering of 16,741,573 common shares with accompanying warrants to purchase 8,370,786 shares at a price of $4.45 per unit. The offering aims to raise approximately $74.5 million in gross proceeds, intended for funding ongoing clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM), as well as for working capital. The offering is expected to close around February 1, 2021, subject to customary conditions.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) has announced a public offering of its common stock and pre-funded warrants, expected to support its clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM) programs. The offering, managed by Stifel, Wells Fargo Securities, and MTS Health Partners, is subject to market conditions. AGTC aims to utilize net proceeds for ongoing trials and general corporate purposes. A registration statement has been filed with the SEC.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) has reported promising preliminary results from its ongoing clinical trials for achromatopsia (ACHM), showcasing sustained improvements in visual sensitivity over 12 months. A patient-by-patient analysis revealed that seven out of sixteen patients in the ACHMB3 trial exhibited enhancements. The company plans to amend its study protocols, including enrolling younger pediatric patients and introducing brain imaging and color brightness tests. AGTC expects to release further data in 2021, pending possible delays due to the COVID-19 pandemic.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced participation by CEO Sue Washer in the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021. The fireside chat will be available on-demand starting January 11, 2021, at 6:00 AM ET. AGTC focuses on AAV-based gene therapies for rare inherited diseases and is advancing clinical programs for retinal diseases like X-linked retinitis pigmentosa and achromatopsia. The company's expertise in gene therapy technology positions it as a leader in developing treatments for significant unmet clinical needs.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) reported financial results for Q1 2020, highlighting a net loss of $15.4 million, increased R&D expenses at $11.6 million, and a cash balance of $66.6 million as of September 30, 2020. The company aims to advance its clinical trials for X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM), with plans to initiate the Phase 1/2 expansion trial (Skyline) in Q4 2020 and the Phase 2/3 trial (Vista) in Q1 2021. Positive data from ongoing trials suggests durable visual improvements for XLRP patients.
